Kirin and Blackmores Team Up To Release LC-Plasma in Taiwan

● Kirin Holdings and Kirin's Australian group company Blackmores have jointly developed a product containing Kirin's unique LC-Plasma.
● This is the first product to be jointly developed by the two companies, and the first time LC-Plasma has been sold in Taiwan.
● This product is manufactured in Japan for the Taiwanese market and sold on an e-commerce site.

TOKYO, March 5, 2025 - Kirin Holdings Company, Limited (Kirin Holdings) and Blackmores Limited (Blackmores), Kirin's group company and Australia's leading natural health company, are proud to announce the launch of Blackmores Revolutionary Strain LC Plasma Powder 4 benefits formula / 澳佳寶® 4效特攻億菌革命プラズマ乳酸菌粉末 formulated with Kirin’s unique ingredient LC-Plasma. This new product is made in Japan for the Taiwan market, and will be on sale from March 5th on Blackmores’ Taiwan e-commerce platform ([新品上市] 4效特攻 億菌革命プラズマ乳酸菌 | 全站活動商品推薦 | BLACKMORES｜澳佳寶台灣(https://www.blackmores.com.tw/v2/official/SalePageCategory/541196?sortMode=Curator)) and Taiwan's leading e-commerce mall, momo (【BLACKMORES 澳佳寶】4效特攻 億菌革命乳酸菌*粉末(共15入)-momo(https://www.momoshop.com.tw/goods/GoodsDetail.jsp?i_code=13730851)).

The Kirin Group's Health Science business has ambitious growth plans to expand its products formulated with LC-Plasma in Japan and overseas, as part of the key CSV*1 initiative on health. Since Blackmores joined the Kirin Group in August 2023, the Group has also been exploring value creation opportunities and business models in the health sciences domain to solve health issues for a wide range of consumers in the Asia-Pacific (APAC) region.
1 Creating Shared Value. Creating value that can be shared with consumers and society

Blackmores Revolutionary Strain LC Plasma Powder 4 benefits formula / 澳佳寶® 4效特攻億菌革命プラズマ乳酸菌粉末 is the first product developed in collaboration with Kirin and Blackmores, and notably the first time LC-Plasma will be introduced to Taiwan. Taiwan has continued growth in demand for vitamins and dietary products, buoyed by the growing adoption of more holistic and preventative attitudes to health. Especially, consumers are also becoming more aware of the vital connection between gut health and overall wellbeing, and the digestive segment currently contributes circa. 20% of total VDS market share as the no.1 segment*2. Also, Taiwan was identified as a suitable pilot market with opportunity to expand the sales channels in the future, as the data on the amount of money spent by Taiwanese visitors to Japan on shopping in Japan*4 show Taiwanese favor “Made in Japan”.
2 Source: Euromonitor Sales of Dietary Supplements by Category: Value 2019-2024
3 Source: Euromonitor Sales of Dietary Supplements by Positioning:% Value 2019-2024. Note: 2024 data is provisional and based on part-year estimates.）
4 Source”: Overseas Community Affairs Council, R.O.C.(TAIWAN) Taiwan visitors rank as biggest foreign spenders in Japanin 2023 OCAC.R.O.C.(TAIWAN) – News *(https://www.ocac.gov.tw/OCAC/Eng/Pages/Detail.aspx?nodeid=329&pid=63335480)

Alastair Symington, CEO of Blackmores said: "I am pleased to announce the launch of Blackmores LC Plasma 4 benefits powder in Taiwan. This marks another significant milestone in Blackmores’ and Kirin Health Science expansion strategy. Over the past 40 years, Blackmores has established a strong presence in Asia, earning the trust and loyalty of consumers across diverse markets. Our success is built on the quality of our products and our deep understanding of local regulatory environments and consumer needs.
Taiwan represents a new and exciting opportunity for us to bring our high-quality, trusted products to even more consumers. I am particularly proud of our dedicated teams on the ground, whose local insights and expertise have been instrumental in tailoring our offerings to meet the specific preferences of each market. As we continue to grow, we remain committed to delivering quality natural health solutions across the APAC region."

About Kirin Holdings

Kirin Holdings Company, Limited is an international company that operates in the Food & Beverages domain (Food & Beverages businesses), Pharmaceuticals domain (Pharmaceuticals businesses), and Health Science domain (Health Science business), both in Japan and across the globe.

Kirin Holdings can trace its roots to Japan Brewery which was established in 1885. Japan Brewery became Kirin Brewery in 1907. Since then, the company expanded its business with fermentation and biotechnology as its core technologies, and entered the pharmaceutical business in the 1980s, all of which continue to be global growth centers. In 2007, Kirin Holdings was established as a pure holding company and is currently focusing on boosting its Health Science domain.

Under the Kirin Group Vision 2027 (KV 2027), a long-term management plan launched in 2019, the Kirin Group aims to become A global leader in CSV*, creating value across our world of Food & Beverages to Pharmaceuticals. Going forward, the Kirin Group will continue to leverage its strengths to create both social and economic value through its businesses, with the aim of achieving sustainable growth in corporate value.

* Creating Shared Value. Combined added value for consumers as well as for society at large.

GALLERY